American Society of Hematology Annual Meeting

Book a Meeting With Our Experts at ASH 2019

Daniel Mazzolenis, MD MBA

Therapeutic Area Leader, Non-Malignant-Hematology

Daniel Mazzolenis is responsible for the non-malignant hematology business segment at Syneos Health, a scope that includes hereditary and acquired bleeding disorders, hemoglobinopathies, some hematologic rare diseases, and "advanced therapies" for them. Dr Mazzolenis is a Hematologist, with several years of medical practice prior to joining the Pharma Industry where he served as Medical Director and Product Manager for Hemophilia in major multinational Pharmas, and Country Manager and Medical Director in CROs. Dr. Mazzolenis earned his MD in 1984 and completed residencies in Internal Medicine and Hematology. He has earned post-graduate University degrees in Clinical Pharmacology and an MBA. 

Patrick M. Nealon

Executive Vice President and General Manager Oncology

Patrick Nealon has over 30 years of global clinical development experience in the Pharmaceutical, Biotechnology and Medical Device industries. Responsible to drive the Oncology business through the creation of appropriate therapeutic strategies and to ensure execution and quality deliverables for our Syneos Health customers. Held a number of leadership positions, a majority of which were based in Global Clinical Operations and Global Program Management for companies such as Astra USA, Genzyme, Takeda, Baxalta, Shire and Servier Pharmaceuticals.
 

Patrick Melvin

Vice President, Therapeutic Area Head, Hematology/Oncology

Patrick Melvin has managed malignant and non-malignant hematology programs, ranging from first-in-human studies through global phase III programs, for the last 22 years. This hematology experience spans all of the major hematologic indications including many rare indications and rare sub-types. His early phase hematology experience includes multiple variations of early phase designs, including PK/PD studies, traditional dose-escalating maximum tolerated dose studies, and many novel/adaptive early phase study designs. His later phase study experience includes extensive global experience in hematology, including full Clinical Development Plan management with customers in the US, EU/CEE, Latin America, and Asia. Over the last five years, much of Patrick’s focus has been in working with customers to launch and manage novel trial designs (including umbrella/master trials, basket trials) for novel hematology indications (I/O, CAR-T, and other cell and gene therapies). Patrick is a charter member of the Cell and Gene Therapy Consortium at Syneos Health, and consults with many customers in this space.

Poster Presentation

Under Reporting of Patient Reported Outcomes (PRO) in Myeloproliferative Neoplasms (MPN) Clinical Trials
Monday, December 9th | 6:00午後-8:00午後
Session Name:  903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III
Presenters: Anthony Messina, Sr. Clinical Research Associate, Liat Vidal, MD, Sr. Medical Director

Meet Our Presenters

Anthony Messina, MSc, CCRP

Sr. Clinical Research Associate

Anthony Messina is a Sr. Clinical Research Associate, focused on patient-centric drug development. He is currently pursuing a Ph.D. in translational health science, where his research centers on the incorporation, utilization and dissemination of patient-reported outcome (PRO) data in oncology clinical research, as well as efforts to improve clinical trial population diversification. Mr. Messina holds a master’s of health science in clinical research administration from George Washington University, a bachelor of science in biology from Florida Atlantic University, and is a Certified Clinical Research Professional of the Society of Clinical Research Associates (SOCRA).

Liat Vidal-Fisher, MD, MSc

Sr. Medical Director

Dr. Liat Vidal is board certified hematologist with more than 10 years' experience in academic and clinical in a large tertiary cancer center. She has been principal and co-author of numerous publications in peer-reviewed journals and held editorial review responsibilities for several publications. Dr. Vidal has specific expertise in conducting meta-analyses and has published several evidence changing articles related to the treatment and management of hem/onc patients. In addition, she has participated as the principal investigator and sub-investigator in multiple industry and investigator-initiated trials.